Guía de Práctica Clínica sobre Cuidados Paliativos - Cedepap TV

159. Congleton J, Muers MF. The incidence of airflow obstruction in bronchial carcinoma, its relationto breathlessness, and response to bronchodilator therapy. Respiratory Medicine.1995;89(4):291-6.160. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessnessin palliative care? A systematic review. Palliat Med. 2007;21(3):177-91.161. Gallagher R, Roberts D. A systematic review of oxygen and airflow effect on relief of dyspneaat rest in patients with advanced disease of any cause. Journal of Pain & Palliative Care Pharmacotherapy.2004;18(4):3-15.162. Booth S, Wade R, Johnson M, Kite S, Swannick M, Anderson H. The use of oxygen in thepalliation of breathlessness. A report of the expert working group of the Scientific Committeeof the Association of Palliative Medicine. Respir Med 2004;98(1):66-77.163. Jennings A-L, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE. A systematic review of theuse of opioids in the management of dyspnoea. Thorax. 2002;57(11):939-44.164. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, doubleblind, placebo controlled crossover trial of sustained release morphine for the managementof refractory dyspnoea. BMJ. 2003;327(7414):523-8.165. Viola R, Kiteley C, Lloyd N, Mackay JA, Wilson R, and the Supportive Care GuidelinesGroup. The Management of Dyspnea in Cancer Patients: A Clinical Practice Guideline. AQuality Initiative of the Program in Evidence-based Care (PEBC). Disponible en: www cancercareon ca/ [accedido en: septiembre 2007] 2007166. Navigante AH, Cerchietti LCA, Castro MA, Lutteral MA, Cabalar ME. Midazolam as AdjunctTherapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with AdvancedCancer. Journal of Pain and Symptom Management. 2006;31(1):38-47.167. Eng D. Management guidelines for motor neurone disease patients on non-invasive ventilationat home. Palliat Med. 2006;20(2):69-79.168. Watson MS, Lucas C.F, Hoy AM, Back IN. Respiratory symptoms. Oxford Handbook ofPalliative Care. New York: Oxford University press; 2005. p. 295-307.169. Homsi J, Walsh D, Nelson KA. Important drugs for cough in advanced cancer. Support CareCancer. 2001;9(8):565-74.170. Estfan B, LeGrand S. Management of cough in advanced cancer. J Support Oncol. 2004;2(6):523-7.171. Lester JF, Macbeth FR, Toy E, Coles B. Palliative radiotherapy regimens for non-small celllung cancer. Cochrane Database Syst Rev. 2006;(4):CD002143.172. Kvale PA. Chronic cough due to lung tumors: ACCP evidence-based clinical practice guidelines.Chest. 2006;129(1 Suppl):147S-53S.173. Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK, et al. The role of highdose-ratebrachytherapy in the palliation of symptoms in patients with non-small-cell lungcancer: A systematic review. Brachytherapy. 2006;5(3):189-202.174. Homsi J, Walsh D, Nelson KA, Sarhill N, Rybicki L, LeGrand SB, et al. A phase II study ofhydrocodone for cough in advanced cancer. American Journal of Hospice and PalliativeMedicine. 2002;19(1):49-56.175. Luporini G, Barni S, Marchi E, Daffonchio L. Efficacy and safety of levodropropizine anddihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur RespirJ. 1998;12(1):97-101.296 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS